Fasenra® (benralizumab) Subcutaneous Injection 30 mg | AstraZeneca Access 360™

Access and Reimbursement Guide

The AstraZeneca Access 360™ program provides personal support to connect patients to affordability programs and streamline access and reimbursement for FASENRA.

For more information, call Access 360 at **1-833-360-4357**, Monday through Friday, 8 AM to 6 PM ET.

1-833-360-HELP
(1-833-360-4357)

1-833-FAX-A360
(1-833-329-2360)

www.MyAccess360.com

Access360@AstraZeneca.com

INDICATION

FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

- FASENRA is not indicated for treatment of other eosinophilic conditions
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to benralizumab or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These reactions generally occur within hours of administration, but in some instances have a delayed onset (ie, days). Discontinue in the event of a hypersensitivity reaction.

Please see additional Important Safety Information throughout this guide and full Prescribing Information including Patient Information.

Prior Authorization and Appeal Checklists

These checklists are intended to simplify the prior authorization (PA) and denial/appeal process for FASENRA® (benralizumab) subcutaneous injection.*

PRIOR AUTHORIZATION (PA) CHECKLIST

The items below may be necessary to obtain a PA decision from a health plan. Please ensure you have all information below prior to submitting the PA.

☐ **Completed PA request form (some health plans require specific forms)** including the following:

- ☐ Patient name, insurance policy number, and date of birth
- ☐ Physician name and NPI number
- ☐ Facility name and NPI number
- ☐ Date of service
- ☐ Patient diagnosis (ICD-10 code[s])
- ☐ Relevant procedure and HCPCS codes for services/products to be performed/provided
- ☐ Product NDC
- ☐ Setting of care

☐ **Letter of medical necessity and relevant clinical support**

- ☐ Include the Provider ID number in the letter

☐ **Documentation that supports the treatment decision, such as:**

- ☐ Previous given treatments/therapies
- ☐ Patient-specific clinical notes detailing the relevant diagnosis
- ☐ Relevant laboratory results
- ☐ Product Prescribing Information

Prior authorization requirements vary by health plan and may require pre-approval. Please contact the patient's health plan for specific PA requirements to ensure efficient and timely review. Failure to obtain prior authorization can result in non-payment by the plan.

Prior to submission, please keep track of dates and methods of correspondence (phone, email, and written); record the names of insurance contacts and reviewers with whom you speak; and summarize conversations and written documents issued by the insurer.

DENIAL AND APPEAL CHECKLIST

If the health plan denied a PA for an AstraZeneca medicine:

☐ **Review the denial notification** to understand the reason and circumstances that need to be addressed and explained in the appeal letter.

☐ **Understand the plan's most recent explanation of benefits** or contact a representative at the insurer to verify where the appeal should be sent and any deadlines.

☐ **Write an appeal letter.** If you need additional information regarding this process, please contact Access 360 for examples.

If you or your patient have not received a decision within 30 days:

☐ **Follow up with the health plan.** Confirm that the appeal letter was received and ask about its status. If the coverage denial was upheld, you could resubmit another appeal with new information or ask for a Supervisor or Manager to assist.

If the denial is upheld again:

☐ **Ask for a one-time exception or consider filing a complaint** with the state's insurance commissioner.

☐ **If the insurer continues to deny the claim:** Your patient may request an external appeal (the process varies by state law), in which an independent third party will review the claim and make a final, binding decision.

☐ Please contact your Field Reimbursement Manager (FRM) or Access 360 if you need additional support.

***Providers and patients are encouraged to contact the patient's insurer for detailed instructions on completing a PA or how to appeal/overturn a denial. If you have any questions, or need guidance, please contact AstraZeneca Access 360™ or your Field Reimbursement Manager at 1-833-360-HELP (1-833-360-4357).**

IMPORTANT SAFETY INFORMATION (cont'd)

Acute Asthma Symptoms or Deteriorating Disease
FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Please see additional Important Safety Information throughout this guide and full Prescribing Information including Patient Information.

Coding

It is important to note that the codes identified below are examples only. Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient. The use of the following codes does not guarantee reimbursement.

National Drug Code (NDC)

10-digit NDC

Administration Method	Dosage	Code
Physician-Administered	FASENRA® (benralizumab) subcutaneous injection 30 mg/mL single-dose prefilled syringe	0310-1730-30
Self-Administered	FASENRA Pen 30 mg/mL single-dose autoinjector	0310-1830-30

11-digit NDC

Administration Method	Dosage	Code
Physician-Administered	FASENRA 30 mg/mL single-dose prefilled syringe	00310-1730-30
Self-Administered	FASENRA Pen 30 mg/mL single-dose autoinjector	00310-1830-30

Current Procedural Terminology® (CPT)[1]

	Code	Description
Injection Administration	96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
	96401	Chemotherapy administration, subcutaneous or intramuscular; nonhormonal antineoplastic
Injection Education	99211	Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified healthcare professional

Healthcare Common Procedure Coding System (HCPCS)[2]

Code	Description	Package Size	Billing Units
J0517	Injection, benralizumab, 1 mg	30 mg/mL single-dose prefilled syringe/autoinjector	30

Diagnosis Codes[3]

ICD-10-CM	Description
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J82.83	Eosinophilic Asthma

HCPCS modifier used to report zero drug wastage.[4,5]

Modifiers provide a means to report or indicate that a service or procedure has been altered by some specific circumstance but not changed in its definition or code. The modifier below may be applicable in physician offices and hospital outpatient departments.

Modifier	Description	Indication and placement
JZ	Zero drug amount discarded/not administered to any patient	Modifier used to report no wastage from single-use vials • CMS claims should include the JZ modifier when no wastage has occurred; other payer requirements may vary • Typically, the modifier is appended to the drug HCPCS code on the same line

IMPORTANT SAFETY INFORMATION (cont'd)

Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection
It is unknown if FASENRA will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves.

CMS–1500 Example Claim Form

Prescribers use this form when billing insurers for medication administered in the physician's office and for their professional services.



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA

1. MEDICARE [X] (Medicare#) MEDICAID [ ] (Medicaid#) TRICARE [ ] (ID#/DoD#) CHAMPVA [ ] (Member ID#) GROUP HEALTH PLAN [X] (ID#) FECA BLK LUNG [ ] (ID#) OTHER [ ] (ID#)

1a. INSURED'S I.D. NUMBER (For Program in Item 1): 123456789

2. PATIENT'S NAME (Last Name, First Name, Middle Initial): Smith, Karen, A

3. PATIENT'S BIRTH DATE MM DD YY; SEX M [ ] F [X]

4. INSURED'S NAME (Last Name, First Name, Middle Initial): Smith, Karen, A

5. PATIENT'S ADDRESS (No., Street): 123 Main St.

6. PATIENT RELATIONSHIP TO INSURED: Self [X] Spouse [ ] Child [ ] Other [ ]

7. INSURED'S ADDRESS (No., Street): 123 Main St.

CITY: New York; STATE: NY

8. RESERVED FOR NUCC USE

CITY: New York; STATE: NY

ZIP CODE: 10001; TELEPHONE (Include Area Code): (212) 555-6789

ZIP CODE: 10001; TELEPHONE (Include Area Code): (212) 555-6789

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

a. OTHER INSURED'S POLICY OR GROUP NUMBER

a. EMPLOYMENT? (Current or Previous) YES [ ] NO [X]

a. INSURED'S DATE OF BIRTH MM DD YY: 3 14 1949; SEX M [ ] F [ ]

b. RESERVED FOR NUCC USE

b. AUTO ACCIDENT? YES [ ] NO [X] PLACE (State)

b. OTHER CLAIM ID (Designated by NUCC)

c. RESERVED FOR NUCC USE

c. OTHER ACCIDENT? YES [ ] NO [X]

c. INSURANCE PLAN NAME OR PROGRAM NAME

d. INSURANCE PLAN NAME OR PROGRAM NAME

10d. CLAIM CODES (Designated by NUCC)

d. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES [ ] NO [X] If yes, complete items 9, 9a, and 9d.

READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM.

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

SIGNED Karen Smith DATE

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

SIGNED Karen Smith

14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY: 01 02 2019 QUAL.

15. OTHER DATE QUAL. MM DD YY

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION MM DD YY FROM TO

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE

17a.

17b. NPI

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES MM DD YY FROM TO

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB? YES [X] NO [ ] $ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind.

A. B. C. D. E. F. G. H. I. J. K. L.

22. RESUBMISSION CODE ORIGINAL REF. NO.

23. PRIOR AUTHORIZATION NUMBER

24. A. DATE(S) OF SERVICE From MM DD YY	To MM DD YY	B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS	MODIFIER	E. DIAGNOSIS POINTER	F. $ CHARGES	G. DAYS OR UNITS	H. EPSDT Family Plan	I. ID. QUAL.	J. RENDERING PROVIDER ID. #
1 01 02 19	01 02 19	11		J0517	JZ					NPI	
2 01 02 19	01 02 19	11		96XXX						NPI	
3										NPI	
4										NPI	
5										NPI	
6										NPI	

25. FEDERAL TAX I.D. NUMBER SSN EIN: 12345

26. PATIENT'S ACCOUNT NO.: 12345

27. ACCEPT ASSIGNMENT? (For govt. claims, see back) YES [ ] NO [ ]

28. TOTAL CHARGE $

29. AMOUNT PAID $

30. Rsvd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)

John Doe MD SIGNED DATE

32. SERVICE FACILITY LOCATION INFORMATION

Pulmonary Specialists of Springfield
123 Main St. Springfield Anytown USA

a. NPI b.

33. BILLING PROVIDER INFO & PH # ( )

Pulmonary Specialists of Springfield
123 Main St. Springfield Anytown USA

a. NPI b.

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

CARRIER

PATIENT AND INSURED INFORMATION

PHYSICIAN OR SUPPLIER INFORMATION

Input Diagnosis Code(s) here

Complete Sections E-J

Input JZ modifier to report no wastage.

The suggestions contained on this form are for example only and AstraZeneca makes no representation that the information is accurate or that it will comply with the requirements of any particular payer/insurer. Providers are solely responsible for determining the billing and coding requirements applicable to any payer/insurer. The information provided here is not intended to be conclusive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. AstraZeneca makes no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use. The use of this information does not guarantee payment or that any payment received will cover your costs.

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5%) include headache and pharyngitis.

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo.

UB–04 Example Claim Form

Hospitals use this form when billing insurers for medication administered in the inpatient or outpatient setting. Outpatient hospitals should bill with the appropriate revenue code.



42 REV. CD.	43 DESCRIPTION	44 HCPCS / RATE / HIPPS CODE
0263	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	96XXX
0636	DRUG/DETAIL CODE FASENRA (benralizumab) 30 mg/mL single-dose prefilled syringe	J0517 JZ NDC: 0310-1730-30

PAGE ____ OF ____ CREATION DATE TOTALS

50 PAYER NAME	51 HEALTH PLAN ID	54 PRIOR PAYMENTS	55 EST. AMOUNT DUE	56 NPI
A Medicare	1234567890			57 OTHER PRV ID

58 INSURED'S NAME	60 INSURED'S UNIQUE ID	61 GROUP NAME	62 INSURANCE GROUP NO.
A Karen Smith	123456789		

63 TREATMENT AUTHORIZATION CODES	64 DOCUMENT CONTROL NUMBER	65 EMPLOYER NAME

1	3a PAT. CNTL #	4 TYPE OF BILL
2	b MED. REC. #	131
	5 FED. TAX NO. 12345678	6 STATEMENT COVERS PERIOD FROM THROUGH

8 PATIENT NAME	9 PATIENT ADDRESS			
a Karen Smith	a 123 Main St.			
b	b New York	c NY	d 10001	e

10 BIRTHDATE	11 SEX	12 ADMISSION DATE	13 HR	14 TYPE	15 SRC	16 DHR	17 STAT	29 ACDT STATE	30
03/19/1949	F	01/02/2019							

76 ATTENDING	NPI	QUAL	
LAST		FIRST	
77 OPERATING	NPI	QUAL	
LAST		FIRST	
78 OTHER	NPI	QUAL	
LAST		FIRST	
79 OTHER	NPI	QUAL	
LAST		FIRST	

74 PRINCIPAL PROCEDURE CODE DATE: 09/03/2016

80 REMARKS

UB-04 CMS-1450 APPROVED OMB LIC921357 THE CERTIFICATIONS ON THE REVERSE APPLY TO THIS BILL AND ARE MADE A PART HEREOF.

Input JZ modifier to report no wastage.

Input Diagnosis Code(s) here

The suggestions contained on this form are for example only and AstraZeneca makes no representation that the information is accurate or that it will comply with the requirements of any particular payer/insurer. Providers are solely responsible for determining the billing and coding requirements applicable to any payer/insurer. The information provided here is not intended to be conclusive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. AstraZeneca makes no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use. The use of this information does not guarantee payment or that any payment received will cover your costs.

IMPORTANT SAFETY INFORMATION (cont'd)

USE IN SPECIFIC POPULATIONS

A pregnancy exposure registry monitors pregnancy outcomes in women exposed to FASENRA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/fasenra.

The data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

Please see additional Important Safety Information throughout this guide and full Prescribing Information including Patient Information.

Understanding Medicare

How prescription coverage works under Medicare

Medicare is a federal health insurance program that mainly provides coverage for people who are over the age of 65, blind, or disabled. This program pays for medical services and procedures that have been determined as "reasonable and necessary." It is important to note that there are various parts of Medicare, and benefits vary based on the type of coverage you select.

Medicare Part A

Hospital Insurance:

Covers inpatient hospital services and certain follow-up care.

Medicare Part B

Medical Insurance:

Covers medically necessary services and supplies. Also covers drugs prescribed and administered by a healthcare provider.

Medicare Part C

Medicare Advantage:

Covers Part A and Part B benefits and could also include prescription coverage.

Medicare Part D

Medicare Prescription Drug Coverage:

These are private insurance plans specifically for prescription drug coverage.

Which prescription drugs are covered under Medicare Part B?

In general, Medicare Part B covers drugs that are not self-administered. This includes drugs given by healthcare providers in their offices and drugs infused in outpatient settings. The yearly Part B deductible usually covers these drugs.

Please see additional Important Safety Information throughout this guide and full Prescribing Information including Patient Information.

INDICATION

FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

- FASENRA is not indicated for treatment of other eosinophilic conditions
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to benralizumab or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These reactions generally occur within hours of administration, but in some instances have a delayed onset (ie, days). Discontinue in the event of a hypersensitivity reaction.

Acute Asthma Symptoms or Deteriorating Disease

FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if FASENRA will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5%) include headache and pharyngitis.

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo.

USE IN SPECIFIC POPULATIONS

A pregnancy exposure registry monitors pregnancy outcomes in women exposed to FASENRA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/fasenra.

The data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

Please read full Prescribing Information, including Patient Information.

You may report side effects related to AstraZeneca products.

Fasenra® (benralizumab) Subcutaneous Injection 30 mg

The AstraZeneca Access 360™ program provides personal support to connect patients to affordability programs and streamline access and reimbursement for FASENRA® (benralizumab) subcutaneous injection.

For more information, call Access 360 at **1-833-360-4357**, Monday through Friday, 8 AM to 6 PM ET.

1-833-360-HELP (1-833-360-4357)

1-833-FAX-A360 (1-833-329-2360)

www.MyAccess360.com

Access360@AstraZeneca.com

References: 1. American Medical Association. *CPT® 2019 Professional Edition*. Chicago, IL: American Medical Association; 2019. **2.** Centers for Medicare & Medicaid Services. HCPCS Release & Code Sets. Alpha-Numeric HCPCS File. November 18, 2020. **3.** American Medical Association. *ICD-10-CM 2019: The Complete Official Codebook*. Chicago, IL: American Medical Association; 2019. **4.** Centers for Medicare & Medicaid Services. HCPCS Quarterly Update. Accessed March 20, 2023. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update **5.** Centers for Medicare & Medicaid Services. JW modifier: drug/biological amount discarded/not administered to any patient frequently asked questions. Accessed March 20, 2023. https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf

AstraZeneca